Bayesian analysis of real‐world data as evidence for drug approval: Remembering Sir Michael Rawlins
Balázs Szigeti, Lawrence D. Phillips, David Nutt
British Journal of Clinical Pharmacology July 17, 2023 DOI: 10.1111/bcp.15841 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Randomized Placebo-controlled Peer reviewed |
|---|---|
| Keywords | Bayesian probability Prior probability |
| Citations | 13 |
| Key points | Argues that placebo-controlled randomized controlled trials are considered the gold standard of medical research, citing an expert consensus survey that endorsed the statement that results from placebo-controlled trials are more reliable than results from any other study design. |
Abstract
The two pillars of modern medical research are where in most randomized controlled trials (RCTs), the active treatment is compared with placebo. A recent expert consensus survey endorsed the statement that 'Results from placebo-controlled trials are more reliable than results from any other study design',1 reflecting that placebo controlled RCTs are considered to be the gold standard.
Citations in the library
Cited by 7
- The Australia story: Current status and future challenges for the clinical applications of psychedelics British Journal of Pharmacology December 19, 2024
- Is it now time to prepare psychiatry for a psychedelic future? The British Journal of Psychiatry May 20, 2024
- Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects. Neuroscience Applied January 11, 2024
- Comment on: History repeating: guidelines to address common problems in psychedelic science Therapeutic Advances in Psychopharmacology 2024
- MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up. Alcohol and Alcoholism May 14, 2025
and 2 more in the library
Cites 4
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Blinding and expectancy confounds in psychedelic randomized controlled trials Expert Review of Clinical Pharmacology May 26, 2021
- Self-blinding citizen science to explore psychedelic microdosing. Elife March 2, 2021